BNR Intrinsic Value – Burning Rock Biotech Receives Nasdaq Minimum Bid Price Notice
January 6, 2024
🌥️Trending News
Burning Rock Biotech ($NASDAQ:BNR) recently announced that they have received a Nasdaq minimum bid price notification. Burning Rock Biotech is a leading Chinese-based biotechnology company dedicated to the development, production and commercialization of advanced diagnostic solutions for precision oncology. Their products provide insights into tumor characteristics to enable personalized cancer treatment. The Nasdaq notification also means that Burning Rock is in compliance with all of the listing requirements laid out by the stock exchange. This includes a minimum share price, regular financial reports, and compliance with all securities regulations.
With this notification, Burning Rock can now confidently move forward with its plans to further develop and commercialize its revolutionary oncology products. This news is a strong indicator of Burning Rock’s success in the market and is a testament to their commitment to providing innovative and efficient cancer diagnostics. The Nasdaq minimum bid price notification highlights that Burning Rock Biotech is on track to achieve their goals and will continue to bring value to investors and patients alike.
Stock Price
The stock opened at $1.0 and closed at $1.0, representing a 4.0% increase from its last closing price of 0.9. This news has caused BURNING ROCK BIOTECH’s stock to gain momentum and the company has been commended for its commitment to meeting the Nasdaq listing standards. This could potentially pave the way for the company to be traded publicly in the future, which is great news for shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for BNR. More…
| Total Revenues | Net Income | Net Margin |
| 558.59 | -707.7 | -126.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for BNR. More…
| Operations | Investing | Financing |
| -307.47 | -14.01 | -57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for BNR. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.17k | 303.75 | 8.4 |
Key Ratios Snapshot
Some of the financial key ratios for BNR are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.0% | – | -129.0% |
| FCF Margin | ROE | ROA |
| -67.7% | -49.2% | -38.6% |
Analysis – BNR Intrinsic Value
As GoodWhale, we have conducted an analysis of BURNING ROCK BIOTECH’s wellbeing. Based on our proprietary Valuation Line, we have determined that its intrinsic value is around $10.3. However, currently BURNING ROCK BIOTECH stock is being traded at $1.0, which is an undervaluation of 90.3%. This presents an opportunity for investors to purchase the stock at a discount and potentially profit from the difference between the intrinsic value and the current market price. More…
Peers
The recent years have seen an intensification of the competition in the global cancer diagnostics market. The market is being led by a number of key players such as Burning Rock Biotech Ltd, AroCell AB, bioAffinity Technologies Inc, and Biomark Diagnostics Inc. These companies are engaged in a intense battle to gain a larger share of the pie.
– AroCell AB ($BER:80R)
AroCell AB is a Swedish biotechnology company that develops and sells cell-based products and services for research and diagnostics. The company has a market cap of 12.32M as of 2022 and a return on equity of -16.04%. AroCell’s products and services are used by researchers and clinicians to study the function of cells and to diagnose and treat diseases.
– bioAffinity Technologies Inc ($NASDAQ:BIAF)
BioAffinity Technologies Inc is a life sciences company that develops products to target and modulate biological systems. The company’s products are based on the discovery and use of natural product scaffolds that can be used to create therapeutics, diagnostics, and research tools. The company’s products include TARGET-derived therapeutics, which are small molecule drugs that target disease-related proteins; TARGET-derived diagnostics, which are used to detect the presence of disease-related proteins; and TARGET-derived research tools, which are used to study the function of disease-related proteins.
– Biomark Diagnostics Inc ($OTCPK:BMKDF)
Biomark Diagnostics Inc is a company that provides diagnostic testing services. The company has a market cap of 11.6M and a ROE of 179.57%. The company offers a wide range of services including blood tests, urine tests, and other diagnostic tests.
Summary
Burning Rock Biotech has seen a rise in its stock price following the receipt of a Nasdaq minimum bid price notification. This could indicate an optimistic outlook for investors, as it signals that the company is meeting the minimum requirements for a share price in order to be listed on the exchange. Further analysis of Burning Rock’s financials and fundamentals should be done to assess its current position and potential future prospects. Investors should also research and understand the company’s competitive environment, financial history, management team, and other factors prior to investing.
In addition, investors should take a long-term perspective of the stock, as short-term fluctuations in price do not affect the overall value of the company in the long run.
